Abstract: The present invention is related to novel polysaccharide-protein conjugate vaccine formulation comprising of at least one of Neisseria meningitidis serogroup A, C, Y, W or X synthetic oligosaccharides (Men A, C, Y, W, X), each said oligosaccharide (OS) being conjugated separately to carrier protein, either none or at least one but not exceeding four bacterial capsular polysaccharide (PS) of Men A, C, Y, W or X, each said polysaccharide being conjugated separately to carrier protein, one or more buffer along with pharmaceutically acceptable components/excipients, with or without an adjuvant. The formulation is a mono- or bi- or multi-valent, liquid or lyophilized or a Liquid-Lyo combination formulation providing desired osmolality, desired pH, high stability and desired immunogenicity.

Abstract: The present invention relates to synthesis of novel higher oligomers and process of preparing the same. In particular the present invention relates to the chemical synthesis of oligomers of Neisseria meningitidis serogroup X (‘hereinafter Men-X), more particularly tetramer. The present invention provides Men-X capsular oligomers obtained from synthetic pathway using purified saccharides of specific chain length and provides said novel oligomers as candidates for the development of conjugate vaccine against bacterial meningitis caused due to Men-X infections.

Abstract: The present invention relates to synthesis of novel higher oligomers and process of preparing the same. In particular the present invention relates to the chemical synthesis of oligomers of Neisseria meningitidis serogroup X (‘hereinafter Men-X), more particularly tetramer. The present invention provides Men-X capsular oligomers obtained from synthetic pathway using purified saccharides of specific chain length and provides said novel oligomers as candidates for the development of conjugate vaccine against bacterial meningitis caused due to Men-X infections.